Sep 4Accession Therapeutics submits CTA to the UK MHRA to start Phase 1 first-in-human clinical trial with lead TROCEPT anti-cancer immunotherapy
Apr 25Accession Therapeutics raises £25m to fund company through generation of first clinical data & to advance second candidate
Jul 18, 2023Chief Business Officer appointed at Accession Therapeutics as company prepares for clinical trials
Jan 4, 2023Accession Therapeutics presented some of the exciting preclinical data for our lead programme
Nov 29, 2022Accession Therapeutics is attending the J.P. Morgan 41st Annual Healthcare Conference - January 2023
Nov 21, 2022Accession Therapeutics raises £16.6m to advance potent immunotherapies towards clinical trials
